Cagrilintide
Last reviewed 2026-10-30
Our read Opinion
Randomized phase 2 evidence supports weight-loss activity, with phase 3 development underway. WADA S0 applies to unapproved pharmacological substances such as cagrilintide.
- Type
- Investigational (in trials)
- Regulatory status
- Investigational; not FDA-approved
- Compounding status
- Trial use only
- FDA-approved indications
- None
- Evidence level
- Human trials ongoing
- Routes studied
- —
- WADA
- Prohibited
- Developer
- Novo Nordisk
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to increase fullness through an amylin signal
- —Claimed to add weight loss when combined with semaglutide
Long-acting amylin analogue that activates amylin receptors involved in satiety and reduced food intake.
Cagrilintide is an investigational amylin analogue studied alone and with semaglutide. No marketing authorization was verified; its standalone RENEW 1 study is phase 3.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
0 news items in last 30 days
This is a credible clinical-development candidate, not an established treatment. Combination-trial results should not be presented as proof of identical standalone benefit.
No news yet for this peptide.
More weight loss than semaglutide alone by adding an amylin signal for fullness.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.